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Although bone metabolism is largely under genetic control, the role of nutrition is considerable.
The present study evaluates the effects of chicken eggshell powder, a new source of dietary Ca,
and purified CaCO3 on bone mineral density (BMD) of the lumbar spine and hip. Besides BMD
we also looked at biochemical markers of bone and Ca metabolism. Both Ca sources were pro-
vided in combination with minerals and vitamins including Mg, cholecalciferol and phylloqui-
none. We designed a randomised, double-blind, placebo-controlled study to take place over 12
months. Healthy Caucasian women (n 85), selected by age ($50 and ,70 years), from the data-
bases of general practitioners were recruited by telephone calls. They had to be at least 5 years
post-menopausal, with lumbar spine T-score being . 2 2·5. At baseline, their mean habitual
daily Ca intake was adequate. The women were randomly allocated to: eggshell powder-
enriched (group A; n 24), purified CaCO3-enriched (group B; n 22), or a placebo product
(group C; n 27). BMD was measured at baseline and then after 6 and 12 months of supplemen-
tation as were the biochemical markers bone-specific alkaline phosphatase, amino-terminal pro-
peptide extension of type I collagen, deoxypyridinoline, calcitonin, intact parathyroid hormone,
calcidiol, and urinary Ca. After 12 months of supplementation, only mean BMD of the femoral
neck in group A was significantly increased (P0·014) by 1·75 % (95 % CI 0·18, 3·32) com-
pared with a decrease of 20·60 % (95 % CI 21·92, 0·72) in group C. This increase coincided
with significant decreases in markers of bone resorption and formation. No significant changes
were seen in BMD at other sites, including lumbar spine, nor in groups B and C. No differences
were found between groups A and B, or B and C.
The present study indicates that healthy late post-menopausal women with an adequate Ca
intake at baseline may increase BMD of the hip within 12 months following supplementation
with the chicken eggshell powder-enriched supplement.
Eggshell powder: Calcium carbonate: Bone mineral density: Postmenopausal women
Age-related decrease in bone mass and loss of bone archi-
tecture contribute to bone fragility. Nutritional prevention
strategies, aiming to reduce the risk of fragility fractures,
should therefore start as soon as possible. For women,
bone loss accelerates at the onset of menopause as a
result of a decreased production of oestrogen. This loss is
often not due to nutrient deficiency and cannot substan-
tially be influenced by the diet. Before bone has come into
a new steady state, 5 to 10 years have passed. Nutritional
interventions therefore seem to be most effective following
that period (Heaney, 1996).
At least Ca and vitamin D are recognised as important in
primary prevention strategies and should be present in
nutritional supplements. However, also for Mg and vitamin
K, evidence for positive effects on bone is compelling
(Schaafsma et al. 2001). Mg is thought to prevent Ca leak-
age from bone by regulating the pH of extracellular fluid.
Furthermore, it is necessary for the synthesis of calcitriol
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(Driessens & Verbeeck, 1988). Two studies with post-
menopausal women suggest an effect of Mg on bone
mineral density (BMD) of hip (Rude & Olerich, 1996)
and forearm (Stendig-Lindberg et al. 1993) after 2 years
of supplementation with 250 and 500 mg daily. Vitamin
K is an essential co-factor in post-translation carboxylation
of osteocalcin, which is important for proper mineraliz-
ation of new bone (Sokoll et al. 1997). Post-menopausal
women with fractures of the distal radius were found to
have a low percentage of carboxylated osteocalcin. These
levels increased considerably following supplementation
with 1 mg phylloquinone/d for only 2 weeks (Douglas
et al. 1995). Recently we showed that also relatively
small daily doses of phylloquinone (80mg) can increase
plasma carboxylated osteocalcin levels in post-menopausal
women (Schaafsma et al. 2000). Several studies have
shown positive effects of additional Ca and/or vitamin D
on BMD of the lumbar spine and hip. These effects are
associated with decreased fracture risk (Prince et al.
1995; Dawson-Hughes et al. 1997; Riggs et al. 1998;
Kanis, 1999). The amounts of Ca and vitamin D necessary
for maximum effect are debated (McKane et al. 1996;
Dawson-Hughes, 1998; Vieth 1999). The Ca source used
may influence the final effect on BMD.
Chicken eggshell powder is a rather unknown Ca source.
It contains about 39 % (w/w) elemental Ca with a bioavail-
ability as high as from CaCO3 (Schaafsma & Beelen,
1999). Since it is widely available, it may be a cheap
and effective solution for many Ca-deficient populations.
It is of interest to know that chicken eggshell powder
also contains Sr (on average 380mg/g). This micronutrient
may have an anabolic effect on bone (Reginster et al.
1999). In small studies, eggshell powder showed positive
effects on BMD of the lumbar spine and hip in post-meno-
pausal women with osteoporosis (Makai & Chudacek,
1991; Schaafsma & Pakan, 1999).
Suitable parameters to measure effects of nutritional
intervention on bone in a healthy population are BMD
for bone strength (Kanis, 1999), deoxypyridinoline (D-
Pyr) for bone resorption (Delmas, 1991), and bone-specific
alkaline phosphatase and the amino-terminal propeptide
extension of type I collagen (P1NP; Cabrera et al. 1998)
for bone formation. Carboxylated osteocalcin, expressed
as a percentage from total osteocalcin, is a marker of
bone mineralisation and vitamin K status (Boskey et al.
1998). Parathyroid hormone (PTH) and calcitonin are reg-
ulators of Ca metabolism and provide information about
bone remodelling (Aurbach, 1988). Vitamin D status is
reflected by serum levels of calcidiol (25(OH)D) which is
the precursor of calcitriol (McKenna & Freaney, 1998).
The present paper describes a double-blind, placebo-
controlled, randomised study with healthy Caucasian
post-menopausal women. The aim of the study was to
investigate the effects of two different Ca sources, chicken
eggshell powder and purified CaCO3, on BMD of the
lumbar spine and hip. To support the BMD measurements,
changes in biochemical markers of bone formation (P1NP,
bone-specific alkaline phosphatase, osteocalcin), bone
resorption (D-Pyr) and vitamin K status in bone (under-
carboxylated osteocalcin) were measured. In addition
markers of vitamin D status (25(OH)D) and Ca metabolism
(PTH and calcitonin) were also measured. Both Ca sources
were given in combination with other minerals and vita-
mins, including Mg and the vitamins cholecalciferol and
phylloquinone. Comparisons were made between the two
Ca sources, with baseline, and with placebo.
Methods
Subjects
Apparently healthy Caucasian post-menopausal women
(n 85) were selected from databases of three general prac-
titioners in the village of Eelde in The Netherlands. Selec-
tion criteria used were age ($50 and ,70 years), absence
of acute and chronic illnesses, and no use of medicines
known to interfere with bone metabolism. The general
practitioner assistants asked selected women, by telephone,
if they were interested to participate in the study. The
research assistant visited interested women for the final
inclusion criteria. Women included were at least 5 years
post-menopausal, did not use vitamin and/or mineral prep-
arations known to interfere with bone metabolism, and they
were asked to abstain from artificial sunbathing during the
study period. Finally, following the first dual-energy X-ray
absorptiometry, women with a lumbar spine T-score
,22·5 or evident arthrosis of the lumbar spine or hip, con-
firmed by X-ray photography, were excluded. Post-meno-
pausal age was determined by recall. Participants were
included after informed consent was obtained. Baseline
characteristics are given in Table 1. During the study
twelve women dropped out because of the need for medical
treatments not related to the intervention. The Medical
Ethical Committee of the University Hospital of Groningen
approved the study.
Supplements and diet
Women were randomly allocated to one of three interven-
tion groups. The three supplements used (Table 2) were
chicken eggshell powder (Biomin a.s., Cifer, Slovak
Republic) combined with Mg, cholecalciferol, phylloqui-
none, and a standard mixture of minerals and vitamins
(supplement A), or purified CaCO3 (Calcipural GP; Scora
S.A., Caffiers, France) combined with the same amounts
of minerals and vitamins as supplement A (supplement
B), or a placebo product containing 2·5 g skimmed milk
powder (supplement C). The subjects were instructed to
take the supplements twice daily, suspended in water,
yoghurt or milk. Compliance, expressed as the percentage
of sachets taken, was assessed on the basis of emptied
sachet counts and written checklists. A minimum compli-
ance of 75 % was necessary for evaluation of results. The
intake of Ca was recorded at three occasions during the
study period by means of a food frequency questionnaire
(National Osteoporosis Foundation, 1999). The aim was
to classify Ca intake as low (,800 mg/d), median (800–
1000 mg/d) or high (.1000 mg/d).
Materials and methods
Evening weight and height were measured by standardised
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methods, and BMI was calculated (kg/m2). BMD of the
lumbar spine (L1–L4) in anteroposterior position and of
the hip (total proximal femur, femoral neck, trochanter,
intertrochanter, and Ward’s triangle) was assessed by
dual-energy X-ray absorptiometry on a Hologic QDR
1000 (Hologic Inc., Waltman, MA, USA). The CV was
1 % for the spine and 1·6 % for the hip. Those measure-
ments were done at the start and after 6 and 12 months
of intervention. Blood samples were obtained between
19.00 and 21.00 hours at baseline (September–December)
and after 6 (March–June) and 12 months (September–
December). Serum was stored at 2208C within 1 h.
Second morning urine samples were collected before
food intake and stored in a freezer until analysis. For stan-
dard monitoring, serum albumin, total Ca, phosphate, crea-
tinine, g glutamyl transferase, alanine amino transferase
and aspartate amino transferase were measured (Mega
automated analyser; Merck, Darmstadt, Germany or
Vitros; Johnson & Johnson Diagnostic, Rochester, NY,
USA). Bone formation was studied by assessment of
P1NP (RIA; Orion Diagnostica, Espoo, Finland; intra-
and inter-assay CV were 8·4 % and 9·0 % respectively),
bone-specific alkaline phosphatase (Immuno assay; Metra
Biosystems, Mountain View, CA, USA; intra- and inter-
assay CV were 4·9 % amd 5·5 % respectively), and total
osteocalcin and undercarboxylated osteocalcin before and
Table 1. Baseline characteristics of the study subjects
(Mean values with their standard deviations)
Group*. . . A B C
Mean SD Mean SD Mean SD
Age (years) 60·5† 3·6 59·5†† 3·8 63·5 4·0
Post-menopausal age (years) 9·9†† 4·0 12·1 6·4 14·3 4·6
Weight (kg) 71·4 9·0 75·5 10·4 76·9 11·9
Height (cm) 164·2 5·4 164·5 5·7 163·9 6·1
BMI (kg/m2) 26·5 3·2 28·1 4·8 28·7 4·4
Lumbar spine (AP)
T-score 20·97 0·96 20·73 0·89 20·72 1·17
Z-score 0·51 1·00 0·68 0·87 0·98 1·16
Femoral neck
T-score 21·54 0·95 21·53 0·95 21·06 1·12
Z-score 0·26 1·04 0·05 0·78 0·86 1·07
Total proximal femur
T-score 20·92 0·83 20·77 1·01 20·49 1·00
Z-score 0·20 0·86 0·29 1·03 0·81 0·92
AP, anteroposterior position.
* Group A (n 24), eggshell powder-enriched supplement in combination with minerals and vitamins; Group B
(n 22), purified calcium carbonate-enriched supplement in combination with minerals and vitamins; Group C
(n 27), placebo containing 2·5 g skimmed milk powder.
Mean values were significantly different from those of group C: †P,0·05, ††P,0·01.
Table 2. Composition of the supplements (per sachet) for groups A, B and C*
Nutrient Group A Group B Group C US RDA
Energy (kJ) 3·4 3·4 34 7980
Protein (g) 0·2 0·2 0·7 50
Ca 1200
From eggshell (mg) 500
purified CaCO3 (mg) 500
from milk (mg) 25
Mg (mg) 175 175 2·8 320
Zn (mg) 5 5 0·08 12
Si (mg) 1000 1000 about 70 †
Vitamin A (mg RE) 160 160 3 800
Cholecalciferol (mg) 5 5 0·005 10
Vitamin E (mg a-TE) 5 5 0·007 8
Phylloquinone (mg) 40 40 0·23 65
Vitamin C (mg) 30 30 0·12 60
Thiamine (mg) 700 700 4·6 1000
Riboflavin (mg) 800 800 35 1200
Vitamin B6 (mg) 1000 1000 9·2 1600
Vitamin B12 (mg) 0·5 0·5 0·09 2·0
RDA, recommended dietary allowances for women aged 51–70 years (National
Research Council, 1989; Standing Committee on the Scientific Evaluation of Dietary
Reference Intakes, 1997); RE, retinol equivalents; a-TE, a-tocopherol equivalents.
* For details of subjects and procedures, see Table 1 and pp. 268–269.
† No RDA has been given. Si levels in cows’ milk were found to be about 400mg/l
(Anderson, 1992).
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after extraction with hydroxyapatite, respectively (IRMA;
Medgenix-H-Ost, Fleurus, Belgium; intra-and inter-assay
CV were 3·1 % and 6·4 %, respectively). Carboxylated
osteocalcin is calculated as the difference between under-
carboxylated osteocalcin and total osteocalcin. Calcitonin
(RIA; Nichols Institute, San Juan Capistrano, CA, USA;
intra-and inter-assay CV were 3·5 % and 6·3 % respect-
ively), intact PTH (IRMA; Nichols Institute; intra- and
inter-assay CV were 3·5 % and 6·0 %, respectively) and
25(OH)D (competitive protein binding assay (Chen et al.
1990); intra- and inter-assay CV were 10·0 % and 16·0 %,
respectively) were determined because they are important
(pre-) hormones in bone metabolism. Urine was analysed
for Ca, phosphate, creatinine (Mega, Merck or Vitros;
Johnson & Johnson) and for D-Pyr (HPLC (Beardsworth
et al. 1990); intra-and inter-assay CV was 6·0 %, the CV
within and between 3-week analyses were ,12 % and
,15 %, respectively). The urinary excretion of D-Pyr and
Ca was corrected for urinary creatinine. Premenopausal
D-Pyr reference value (University Hospital Groningen)
was 11·7mmol/mol creatinine (95 % CI 6·8, 23·1).
Statistics
Sample size per group was calculated based upon a small
pilot study (Schaafsma & Pakan, 1999). For this study,
we calculated that at a 95 % level of significance and
90 % power, twenty-one women per group were needed
to detect a difference of 1·4 % in BMD of the femoral
neck between intervention and placebo group. We aimed
to include twenty-five women per group.
Allocation to the different intervention groups was based
on computer-generated random numbers. Data were ana-
lysed using SPSS 7.0 (SPSS Inc., Chicago, USA).
Before the main analysis, P1NP, body weight and post-
menopausal years at baseline were identified as potential
confounders by forward multiple regression. However,
the variables appeared not to be of significant importance
in the univariate general linear model, using the change
in femoral neck BMD as dependent variable. Therefore,
these confounders were not taken into consideration
during the main analysis, in order to keep the model as
simple as possible.
Some of the parameters (post-menopausal age, weight,
BMI, P1NP, calcitonin, PTH, and BMD lumbar spine)
were found to have non-parametric distributions according
to the Kolmogorov–Smirnov normality test. For that
reason, all parameters were evaluated with non-parametric,
two-tailed statistical tests. Differences between the groups
were studied with the Kruskal–Wallis test combined with
the Mann–Whitney U-test. Differences between repeated
measurements within the groups were identified with the
Wilcoxon signed-rank test. Associations between baseline
values of parameters and their changes after 12 months
were studied with the Spearman rank test. Differences
were considered significant when P#0·05. Changes in par-
ameters were calculated as percentage change from
baseline.
Results
Age, compliance, calcium intake and routine parameters
Although the women were recruited from the same popu-
lation and randomly allocated to one of the three groups,
women in groups A and B were significantly younger
than those in group C. Furthermore, group A had a signifi-
cantly lower post-menopausal age compared with group C
(Table 1). The number of women with a post-menopausal
age less than 10 years in groups A, B and C accounted
for 58, 45 and 15 %, respectively. These differences in
age and post-menopausal age, however, were not associ-
ated (Spearman rank test) with changes in BMD at any
site. Mean compliance with intervention in groups A, B
and C was 97 (range 90·8–100)%, 98·4 (93·4–100)%
and 97 (82·4–100)%, respectively. The calculated Ca
intake of the participants in the present study was unex-
pectedly high (1294 (SD 421) mg/d) when compared with
the mean Dutch (Dutch National Food Consumption
Table 3. Bone mineral densities (g/cm2) at baseline and their percentage changes after 12 months of
intervention*
(Mean values with their standard deviations)
Group. . . A B C
Site of measurement Mean SD Mean SD Mean SD
Lumbar spine: Baseline 0·936 0·105 0·966 0·099 0·968 0·129
Change (%) 0·10 2·14 0·52 2·07 0·13 2·31
Femoral neck: Baseline 0·741 0·095 0·741 0·095 0·792 0·114
Change (%) 1·75†‡ 3·91 1·16 5·09 20·60 3·50
Total proximal femur: Baseline 0·864 0·099 0·883 0·121 0·917 0·120
Change (%) 0·23 3·59 0·23 3·57 20·14 4·34
Trochanter: Baseline 0·649 0·073 0·671 0·092 0·696 0·091
Change (%) 20·31 3·00 20·46 5·24 0·57 6·47
Intertrochanter: Baseline 1·016 0·126 1·038 0·156 1·073 0·159
Change (%) 0·20 3·94 0·29 4·53 20·28 4·85
Ward’s triangle: Baseline 0·592 0·138 0·539 0·125 0·609 0·129
Change (%) 3·38†† 5·07 4·08 10·76 20·50 6·24
* For details of subjects and procedure, see Tables 1 and 2 and pp. 268–269.
Mean values at 12 months were significantly different from those at baseline: †P0·013, ††P0·006.
Mean change at 12 months was significantly different from that of group C: ‡P0·014.
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Survey, 1998) daily Ca intake by 50–65-year-old women
(995 mg). Habitual Ca intake did not differ between the
groups at baseline and did not change during the study.
No significant differences were found in body weight,
height, and BMI between the groups at baseline (Table 1)
nor were changes observed during the study. Serum con-
centrations of Ca, phosphate, creatinine, albumin and the
enzymes g glutamyl transferase, alanine amino transferase
and aspartate amino transferase also did not change during
the study (result not shown).
Bone mineral density
Despite the age differences between the groups, BMD
baseline values were not significantly different (Table 3).
After 12 months of intervention, BMD of femoral neck
and of Ward’s triangle had increased significantly in
group A compared with baseline. No significant changes
were seen in BMD at other sites nor in groups B and
C. No differences were found between groups A and
B. The increase in BMD of the femoral neck in group A
was significantly different from the decrease in group C,
which is in accordance with the calculated statistical
power of the study.
Effects of baseline BMD on BMD changes after 12
months were studied for the combined groups A and B,
since these groups only differed in Ca source. Low baseline
BMD in groups A and B were associated (P,0·01) with
larger increases or smaller losses after 12 months in case
of the intertrochanter (r 20·45), total proximal femur
(r 20·39), and the Ward’s triangle (r 20·41). In contrast,
lumbar spine BMD increased more or decreased less
when baseline BMD was higher (r 0·39, P,0·01). No
significant correlations were found for the femoral neck
and trochanter.
Biochemical markers
Baseline values of biochemical markers and changes (%)
after 12 months are reported in Table 4. Only one
woman in group C had a marginal (25–40 nmol/l (Vieth,
1999)) 25(OH)D level at baseline. All three groups had
increased their serum 25(OH)D levels significantly at the
end of the study. For group C, the increase is probably
due to the summer, since this group was not supplemented
with vitamin D. During the winter months, the mean
25(OH)D level in group C decreased by 26 % to
67 nmol/l. Both intervention groups did not show a
winter dip of 25(OH)D. In both supplemented groups,
serum levels of P1NP and PTH decreased significantly
compared with baseline. The percentage changes in
P1NP and PTH were also different from the percentage
changes in group C. No differences were found in levels
of total osteocalcin. Carboxylated osteocalcin increased
during the study in group B. A significant decrease in
D-Pyr excretion was found in group A. This group also
had the highest baseline excretion of D-Pyr. Group C
showed a small but significant increase in bone-specific
alkaline phosphatase compared with baseline and com-
pared with groups A and B. No differences were found
between groups A and B in changes and absolute levels
of biochemical parameters at 12 months. Only at 6
months was the decrease in D-Pyr significantly (P0·04)
greater in group A compared with group B (result not
shown).
When groups A and B were combined, all baseline
Table 4. Biochemical parameters at baseline and percentage changes from baseline after 12 months of intervention*
(Mean values with their standard deviations)
Group. . . A B C P value†
Parameter Mean SD Mean SD Mean SD A v. C B v. C
b-ALP (U/l) Baseline 16·2 4·5 17·4 6·4 14·8 3·8
Change (%) 2·2 12·5 22·8 21·6 9·9‡‡‡ 13·3 0·015 0·012
P1NP (mg/l) Baseline 45·9 14·3 47·2 20·5 37·0 13·3
Change (%) 217·6‡‡ 23·2 218·2‡‡‡ 19·5 27·0 21·0 0·029 0·015
Calcitonin (ng/l) Baseline 8·1 3·5 8·0 2·6 6·4 2·5
Change (%) 8·7 37·4 24·0 17·7 8·4 25·5
Intact-PTH (pmol/l) Baseline 5·5 1·3 5·8 1·9 5·4 1·7
Change (%) 215·4‡ 26·6 219·5‡ 42·6 6·5 35·3 0·019 0·010
Calcidiol (nmol/l) Baseline 97·1 24·1 83·1 22·4 91·0 36·5
Change (%) 25·1‡‡‡ 29·8 43·8‡‡‡ 27·3 11·1‡ 22·7 0·000
D-Pyr (mmol/mol Creatinine) Baseline 15·0 4·3 12·6 3·2 12·2 3·8 0·023
Change (%) 214·9‡‡ 25·1 22·4 26·9 1·6 23·6 0·011
%carbOC (%) Baseline 67·3 9·0 67·1 7·4 66·4 10·2
Change (%) 5·0 12·3 6·9‡ 14·3 21·8 15·8 0·014
Total osteocalcin (mg/l) Baseline 13·9 5·2 13·9 4·1 12·4 4·4
Change (%) 21·7 26·7 22·4 24·8 0·4 17·7
Urinary Ca:creatinine (mol/mol) Baseline 0·44 0·31 0·42 0·18 0·37 0·23
Change (%) 10·9 70·9 23·4 74·5 20·2 56·7
b-ALP, bone-specific alkaline phosphatase; P1NP, amino-terminal propeptide extension of type I collagen; PTH, parathyroid hormone; D-Pyr, deoxypyridinoline;
%carbOC, carboxylated osteocalcin.
* For details of subjects and procedures, see Tables 1 and 2 and pp. 268–269.
† Mann-Whitney U test between the groups.
Baseline and 12 month levels of parameters were significantly different within the group ‡P#0·05, ‡‡P#0·01, ‡‡‡P#0·001 (Wilcoxon signed rank test).
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values of biochemical markers were significantly and
negatively correlated (r 20·33 to 20·80) with the changes
after 6 (except for calcitonin) and 12 months of supplemen-
tation. For the parameters P1NP, D-Pyr and PTH this
means that decreases were stronger where baseline values
were higher (Fig. 1). No correlation was found between
baseline PTH and baseline 25(OH)D, nor between their
changes after 12 months of study. However, in group B
alone, larger increases in 25(OH)D during the study were
associated with larger decreases in PTH (r 20·42,
P#0·05).
Only two significant correlations were found between
BMD and biochemical parameters in the combined
groups A and B. Firstly, the increase in femoral neck
BMD was associated with a decrease in D-Pyr excretion
(r 20·32, P,0·05). Secondly, BMD of the trochanter
showed a higher increase or a smaller decrease when
serum PTH decreased more (r 20·34, P,0·05). These cor-
relations were especially an effect of group B.
Discussion
We investigated the effects of daily supplements with
different Ca sources (chicken eggshell powder: group A,
n 24; purified CaCO3: group B, n 22) but equal amounts
of cholecalciferol, phylloquinone, Mg and other vitamins
and minerals (Table 2), in healthy post-menopausal
women aged 50–70 years (Table 1) during 1 year.
Untreated post-menopausal women (group C, n 27)
served as controls. The major finding at the study end
Fig. 1. Correlations between baseline levels of deoxypyrimidoline (D-Pyr; R2 0·46, r 20·46, P,0·01), amino-terminal propeptide extension of
type I collagen (P1NP; R2 0·18, r 20·42, P,0·01) and parathyroid hormone (PTH; R2 0·19, r 20·36, P,0·05) and their percent changes after
12 months of intervention. Changes in parameters were obtained by subtracting baseline from 12 month values. The calculated difference was
expressed as a percentage from baseline. For a description of the groups A and B, see Table 1; for the supplements, see Table 2. The
regression line (---) accounts for the combined groups A and B. (B) Group A; (K) Group B.
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was an increased BMD of the femoral neck in group A
compared with group C. Compared with baseline, group
A exhibited an increase of BMD in the Ward’s triangle
and femoral neck (Table 3). Changes in BMD were not
different between groups A and B. Both groups exhibited
changes in serum markers of bone resorption (D-Pyr),
bone formation (P1NP) and the 25(OH)D–PTH axis
(Table 4), all together suggesting a reduction of bone turn-
over. Since both an increase of BMD and a reduction of
bone turnover (Lauritzen, 1996; Kanis, 1999) are associ-
ated with increased bone strength and reduced fracture
risk (Compston, 1995; Dawson-Hughes, 1998), we con-
clude that the supplements used in groups A and B are
likely to be beneficial for bone health. It must be pointed
out that BMD changes did not reach significance in
group B, which might be due to somewhat smaller subject
numbers.
Negative correlations between baseline BMD of the hip
and changes after 12 months indicate a higher responsive-
ness of women with low baseline BMD to additional min-
erals and vitamins. Biochemical parameters of bone
turnover also showed such negative correlations between
baseline and changes after 12 months (Fig. 1). These
associations suggest that especially women with high
bone turnover and/or lower baseline BMD of the hip bene-
fited from the supplementation. The encountered positive
correlation between baseline BMD of the lumbar spine
and change after 12 months can possibly be explained by
a higher transient remodelling effect (Heaney, 1996). It is
possible that a higher BMD accounts for a larger surface
area of trabecular bone and consequently more resorption
cavities to fill.
Although increases in BMD of the femoral neck and
Ward’s triangle in group A suggest an increased femoral
strength we did not observe effects on BMD of the trochan-
ter. This might be of importance, since the strength of the
femoral neck seems rather predicted by an increase in
BMD of the trochanter than by that of the femoral neck
itself (Cheng et al. 1997). Our results are in line with
those of Reid et al. (1995), who also found no changes
in trochanter BMD, following a 1 year supplementation
of women 10 years past menopause with 1000 mg Ca/d.
A slight increase from baseline was however noticed
after 4 years of supplementation. It is therefore possible
that prolonged use of the present supplements may also
have favourable effects on trochanter BMD.
Both the Ward’s triangle and lumbar spine are mostly
composed of trabecular bone, whereas the femoral neck
contains more cortical bone (Wood & Fleet, 1998). Trabe-
cular bone often responds better to Ca supplementation
than cortical bone (Kanis, 1999), and it is therefore not
clear why we merely observed increases in BMD of the
Ward’s triangle and femoral neck and not of the lumbar
spine. The relatively low post-menopausal age of the pre-
sent study population might be a factor in this respect. It
is known that oestrogen deficiency during the first 5–10
years past menopause results primarily in a loss of trabecu-
lar bone and this loss is poorly responsive to nutritional
intervention (Compston, 1995; Ohta, et al. 1996). Studies
(Dawson-Hughes et al. 1990; Nelson et al. 1991) with
3–13 years post-menopausal women support this statement
but also show that the effect of oestrogen deficiency on tra-
becular bone might even persist longer than 10 years past
menopause. Fifty-eight percent of group A and 45 % of
group B had post-menopausal ages below 10 years. This
interpretation does not, however, provide us with an expla-
nation for the observed increase of Ward’s triangle BMD.
It is also possible that the increase of femoral neck BMD,
but not the lumbar spine, is caused by an increased intake
of Mg and/or a decreased serum level of PTH. Mg sup-
plementation of post-menopausal women with 500 mg
Mg/d for 2 years gave rise to an increase of especially
the BMD of the femoral neck (Rude & Olerich, 1996). A
high PTH level in post-menopausal women is caused by
oestrogen deficiency, low vitamin D status and/or low Ca
intake and is regarded to decrease especially BMD of cor-
tical bone (Compston, 1995; McKenna & Freaney, 1998).
In this respect it is important to note that serum
25(OH)D levels in the supplemented groups reached
values above 100 nmol/l, which did not decline during
the winter months. These levels are regarded to cause the
lowest achievable PTH levels at a given Ca intake
(McKenna & Freaney, 1998). Furthermore, the decrease
of PTH may partially be due to the increased Ca intake
(up to 2300 mg/d), since a daily intake of over 2000 mg
Ca by elderly women was found to reduce PTH to pre-
menopausal values (McKane et al. 1996).
Directly after menopause, bone turnover increases with
an excess of bone resorption (Allolio, 1999) reflected in
a higher urinary D-Pyr excretion. The older women in
the placebo group therefore probably lost less bone than
was to be expected in the younger women in group B
and group A in particular. In agreement with their lower
post-menopausal age, higher D-Pyr levels in group A at
baseline, compared with group C (Table 4), probably indi-
cate a higher bone turnover. At the same time, the lower
levels of biochemical markers in group C may be explained
by a gradual decrease of oestrogen deficiency-related bone
turnover with advancing post-menopausal age (Ohta et al.
1996). The urinary D-Pyr excretion in group A decreased
within 6 months to levels found in groups B and C,
which were close to premenopausal reference values as
used by the University Hospital of Groningen. Both
groups A and B showed a decrease of P1NP levels,
which is a marker of bone formation and therefore of
bone turnover. Taken together these data suggest that the
supplements taken by groups A and B, reduce bone turn-
over. Recently it has been reported that short-term changes
in biochemical markers may predict long-term changes in
BMD (Ravn et al. 1999). The supplements are therefore
likely to change the balance of bone resorption and bone
formation towards the latter especially when baseline turn-
over is high. This effect is shown particularly in group A
with increases in BMD at certain sites.
Although the focus of this discussion is on Ca, Mg, chole-
calciferol and phylloquinone, other vitamins and minerals
were present, and we cannot exclude that they did not
influence the final results in some way. However, effects
can be explained for the major part by the four key
ingredients (Schaafsma et al. 2001). A second point of
discussion is the compositional difference between
chicken eggshell powder and purified CaCO3. A beneficial
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characteristic of chicken eggshell powder may be the rela-
tively high levels of Sr; normal daily Sr intake increases
15–40 %/g eggshell powder consumed. Although this
chronic loading with Sr may be stimulatory for bone for-
mation in the long-term, the intakes are 400 to 800 times
lower than the amounts used in therapeutic studies
(Schaafsma et al. 2001).
We conclude that in healthy women, close to 10 years
past menopause, supplementation with minerals and vita-
mins, and Ca, Mg, vitamin D and vitamin K in particular,
increases BMD of the femoral neck and Ward’s triangle.
Favourable effects on BMD are supported by decreases
in parameters of bone turnover. The present study also
suggests, based on changes from baseline and compared
with placebo, that eggshell powder may be preferred over
purified CaCO3 as a source of Ca. This suggestion, how-
ever, warrants further research with statistical power
based on the outcome of the present study.
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